Using lung ultrasound to manage fluid overload in hemodialysis patients
Role of Lung Ultrasound in the Assessment and Management of Pulmonary Congestion in Chronic Hemodialysis Patients: A Randomized Controlled Study
NA · Hamad Medical Corporation · NCT06296160
This study tests whether using lung ultrasound can help doctors better manage fluid overload in patients with kidney failure who are on hemodialysis.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Hamad Medical Corporation (industry) |
| Locations | 1 site (Bruxelles, Van Gehuchten) |
| Trial ID | NCT06296160 on ClinicalTrials.gov |
What this trial studies
This study evaluates a lung ultrasound-guided management protocol for assessing pulmonary congestion in patients with end-stage renal disease undergoing hemodialysis. It aims to improve the estimation of dry weight and fluid overload, which are critical for reducing cardiovascular risks associated with hemodialysis. The study compares this novel ultrasound approach to traditional methods such as pulmonary auscultation and chest radiography. By focusing on the relationship between pulmonary congestion and cardiovascular health, the study seeks to enhance patient outcomes in chronic hemodialysis care.
Who should consider this trial
Good fit: Ideal candidates are chronic in-center hemodialysis patients who have been receiving treatment for at least three months.
Not a fit: Patients with active cancer, infections, pulmonary fibrosis, or those experiencing frequent hypotension during hemodialysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce cardiovascular complications in hemodialysis patients by providing more accurate assessments of fluid overload.
How similar studies have performed: Preliminary studies have shown promise for lung ultrasound in assessing pulmonary congestion, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chronic in-center hemodialysis patients for at least three months Exclusion Criteria: * Active Cancer. * Active infection. * Patients with pulmonary fibrosis. * Patients with diffuse pneumonia. * Patients with frequent hypotension episodes in HD * Extreme weight gain between dialysis sessions demanding more than 13 ml/kg/h UF rate.
Where this trial is running
Bruxelles, Van Gehuchten
- Kaysi Saleh — Bruxelles, Van Gehuchten, Belgium (RECRUITING)
Study contacts
- Study coordinator: Abdullah I Hamad, MD
- Email: ahamad9@hamad.qa
- Phone: +97433486848
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: End Stage Renal Disease, Regular Hemodialysis, Fluid overload, lung cognition, Number of B-lines, Lung Ultrasound